HIV reverse transcriptase inhibitors

US7807684B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Sandeep A. Saggar · Charlottesville, US
• John T. Sisko · Lansdale, US
• Thomas J. Tucker · North Wales, US
• Robert Tynebor · Hatfield, US
• Dai-Shi Su · New York, US
• Neville J. Anthony · Hatfield, US

Key dates

• Filing date: Jul 17, 2006
• Grant date: Oct 5, 2010
• Expiry date: Aug 4, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds having the structure:are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.